Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population

Melanoma Research

Volumn 24, Issue 6, 2014, Pages 602-610

  Vekeman, Francis ^a   Cloutier, Michel ^a   Yermakov, Sander ^b   Amonkar, Mayur M ^c   Arondekar, Bhakti ^c   Duh, Mei S ^b  

^a Groupe d'analyse Ltée   (Canada)

^b ANALYSIS GROUP   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Brain metastases; Healthcare costs; Healthcare resource utilization; Metastatic melanoma

Indexed keywords

CARBOPLATIN; DACARBAZINE; IPILIMUMAB; TEMOZOLOMIDE; VEMURAFENIB;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; METASTATIC MELANOMA; MULTIMODALITY CANCER THERAPY; OBSERVATIONAL STUDY; OUTPATIENT CARE; RETROSPECTIVE STUDY; UNITED STATES; AGED; BRAIN TUMOR; COST OF ILLNESS; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE PLANNING; HEALTH INSURANCE; MELANOMA; MIDDLE AGED; PATHOLOGY; SECONDARY; SKIN TUMOR; STATISTICS AND NUMERICAL DATA;

AGED; BRAIN NEOPLASMS; COST OF ILLNESS; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MANAGED CARE PROGRAMS; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; UNITED STATES;

EID: 84916941957     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000097     Document Type: Article

References (17)

1. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am 1996; 7:337-344.
2. Carlino MS, Atkins MB, Warneke CL, Long GV, DeRose ER, Johnson MM, et al. Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study. Pigment Cell Melanoma Res 2010; 23:946.
3. Shapiro DG, Samlowski WE. Management of melanoma brain metastases in the era of targeted therapy. J Skin Cancer 2011; 2011:845-863.
4. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011; 117:1687-1696.
5. Carlino MS, Fogarty GB, Long GV. Treatment of melanoma brain metastases: a new paradigm. Cancer J 2012; 18:208-212.
6. McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, Brown PD. Melanoma-induced brain metastases. Expert Rev Anticancer Ther 2008; 8:743-755.
7. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218.
8. Jakob JA, Bassett RL Jr, Ng CS, Curry JL, Joseph RW, Alvarado GC, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012; 118:4014-4023.
9. Ribas A, Hersey P, Middleton MR, Gogas HJ, Flaherty KT, Sondak VK, Kirkwood JM. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012; 18:336-341.
10. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET. Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother 2012; 12:1207-1215.
11. United States Bureau of Labor Statistics. Consumer Price Index - all urban consumers: CUUR0000SAM; 2013. Available at: http://www.bls.gov/cpi/data.htm. [Accessed 10 April 2013].
12. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130-1139.
13. Davis KL, Mitra D, Kotapati S, Ibrahim R, Wolchok JD. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database. Appl Health Econ Health Policy 2009; 7:31-41.
14. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER) - Medicare data. Arch Dermatol 2010; 146:249-256.
15. Ray S, Dacosta-Byfield S, Ganguli A, Bonthapally V, Teitelbaum A. Comparative analysis of survival, treatment, cost and resource use among patients newly diagnosed with brain metastasis by initial primary cancer. J Neurooncol 2013; 114:117-125.
16. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13:1087-1095.
17. Eichler AF, Lamont EB. Utility of administrative claims data for the study of brain metastases: a validation study. J Neurooncol 2009; 95:427-431.